CO2017004714A2 - Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina - Google Patents

Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina

Info

Publication number: CO2017004714A2
Authority: CO; Colombia
Prior art keywords: dimethylphosphoryl; methylpiperazin; piperidin; pyrimidine; diamine
Prior art date: 2014-10-21

Application number

CONC2017/0004714A

Other languages

English (en)

Spanish (es)

Inventor

W Leonard Rozamus

Pradeep Sharma

Original Assignee

Ariad Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-21

Filing date

2017-05-10

Publication date

2017-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54365447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017004714(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2017-05-10 Application filed by Ariad Pharma Inc filed Critical Ariad Pharma Inc

2017-10-31 Publication of CO2017004714A2 publication Critical patent/CO2017004714A2/es

Links

-1 dimethylphosphoryl Chemical group 0.000 title 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 abstract 1
229950004272 brigatinib Drugs 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/025—Purification; Separation; Stabilisation; Desodorisation of organo-phosphorus compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)

CONC2017/0004714A 2014-10-21 2017-05-10 Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina CO2017004714A2 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201462066849P	2014-10-21	2014-10-21
PCT/US2015/056701 WO2016065028A1 (en)	2014-10-21	2015-10-21	Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine

Publications (1)

Publication Number	Publication Date
CO2017004714A2 true CO2017004714A2 (es)	2017-10-31

Family

ID=54365447

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CONC2017/0004714A CO2017004714A2 (es)	2014-10-21	2017-05-10	Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina

Country Status (32)

Country	Link
US (4)	US10385078B2 (da)
EP (2)	EP3209647B1 (da)
JP (2)	JP6633072B2 (da)
KR (2)	KR102331856B1 (da)
CN (4)	CN111825717A (da)
AU (1)	AU2015335950B2 (da)
CA (1)	CA2965169C (da)
CL (1)	CL2017000979A1 (da)
CO (1)	CO2017004714A2 (da)
CR (1)	CR20170146A (da)
CY (1)	CY1123295T1 (da)
DK (1)	DK3209647T3 (da)
DO (1)	DOP2017000101A (da)
EA (1)	EA035145B1 (da)
EC (1)	ECSP17030878A (da)
ES (1)	ES2813726T3 (da)
HR (1)	HRP20201343T1 (da)
HU (1)	HUE051693T2 (da)
IL (2)	IL251818B (da)
LT (1)	LT3209647T (da)
MX (1)	MX2017005120A (da)
MY (1)	MY192216A (da)
PE (1)	PE20171344A1 (da)
PH (1)	PH12017500732B1 (da)
PT (1)	PT3209647T (da)
RS (1)	RS60737B1 (da)
SG (1)	SG11201702980QA (da)
SI (1)	SI3209647T1 (da)
TN (1)	TN2017000157A1 (da)
UA (1)	UA119794C2 (da)
WO (1)	WO2016065028A1 (da)
ZA (1)	ZA201702737B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2704572B1 (en)	2011-05-04	2015-12-30	Ariad Pharmaceuticals, Inc.	Compounds for inhibiting cell proliferation in egfr-driven cancers
JP6469567B2 (ja)	2012-05-05	2019-02-13	アリアド・ファーマシューティカルズ・インコーポレイテッド	Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9611283B1 (en)	2013-04-10	2017-04-04	Ariad Pharmaceuticals, Inc.	Methods for inhibiting cell proliferation in ALK-driven cancers
US10544129B2 (en)	2016-10-25	2020-01-28	Crystal Pharmatech Co., Ltd.	Crystalline forms of AP26113, and preparation method thereof
CN110520110A (zh) *	2017-03-08	2019-11-29	阿瑞雅德制药公司	包含5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的药物制剂
WO2019148789A1 (zh) *	2018-02-02	2019-08-08	苏州科睿思制药有限公司	布格替尼的晶型及其制备方法
WO2019158421A1 (en)	2018-02-13	2019-08-22	Sandoz Ag	Pharmaceutical composition of brigatinib
RU2020133814A (ru) *	2018-03-19	2022-04-19	Такеда Фармасьютикал Компани Лимитед	Способы лечения рака у пациентов детского возраста
WO2020099483A1 (en)	2018-11-15	2020-05-22	Sandoz Ag	Crystalline forms of brigatinib
US12435023B2 (en) *	2019-05-21	2025-10-07	Shanghai Forefront Pharmceutical Co., Ltd.	Crystal form of Treprostinil sodium salt and preparation method therefor
CN112047978A (zh) *	2019-06-05	2020-12-08	北京赛思源生物医药技术有限公司	5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺新晶型
US20220402948A1 (en) *	2019-09-26	2022-12-22	Betta Pharmaceuticals Co., Ltd.	Egfr inhibitor, composition and preparation method therefor
CN111138492B (zh) *	2020-01-06	2022-08-02	沈阳药科大学	Alk抑制剂布格替尼的制备方法
WO2022127807A1 (zh) *	2020-12-18	2022-06-23	江苏豪森药业集团有限公司	一种芳基磷氧化物类衍生物自由碱的晶型及其制备方法和应用
US20230015697A1 (en) *	2021-07-13	2023-01-19	Citrix Systems, Inc.	Application programming interface (api) authorization
CN115154473A (zh) *	2022-08-04	2022-10-11	中国人民解放军陆军特色医学中心	布格替尼作为axl、c-met、st3gal4抑制剂的新应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
BE758350A (fr) *	1969-12-30	1971-05-03	Pfizer	Procede de fabrication des sels mono- et bi-metalliques alcalins de l'alpha-carboxybenzylpenicilline
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US4270537A (en)	1979-11-19	1981-06-02	Romaine Richard A	Automatic hypodermic syringe
US4432987A (en) *	1982-04-23	1984-02-21	Pfizer Inc.	Crystalline benzenesulfonate salts of sultamicillin
US4736866B1 (en)	1984-06-22	1988-04-12		Transgenic non-human mammals
KR890002631B1 (ko)	1984-10-04	1989-07-21	몬산토 캄파니	생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US4596556A (en)	1985-03-25	1986-06-24	Bioject, Inc.	Hypodermic injection apparatus
US5023252A (en)	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
US4886499A (en)	1986-12-18	1989-12-12	Hoffmann-La Roche Inc.	Portable injection appliance
GB8704027D0 (en)	1987-02-20	1987-03-25	Owen Mumford Ltd	Syringe needle combination
US5001139A (en)	1987-06-12	1991-03-19	American Cyanamid Company	Enchancers for the transdermal flux of nivadipine
US4992445A (en)	1987-06-12	1991-02-12	American Cyanamid Co.	Transdermal delivery of pharmaceuticals
US4790824A (en)	1987-06-19	1988-12-13	Bioject, Inc.	Non-invasive hypodermic injection device
US4940460A (en)	1987-06-19	1990-07-10	Bioject, Inc.	Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en)	1987-06-19	1990-07-17	Bioject, Inc.	Pre-filled ampule and non-invasive hypodermic injection device assembly
US5339163A (en)	1988-03-16	1994-08-16	Canon Kabushiki Kaisha	Automatic exposure control device using plural image plane detection areas
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
FR2638359A1 (fr)	1988-11-03	1990-05-04	Tino Dalto	Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5175383A (en)	1989-02-17	1992-12-29	President And Fellows Of Harvard College	Animal model for benign prostatic disease
IT1229203B (it)	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en)	1989-07-07	1997-12-23	Novartis Inc	Sustained release formulations of water soluble peptides.
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
US5064413A (en)	1989-11-09	1991-11-12	Bioject, Inc.	Needleless hypodermic injection device
US5312335A (en)	1989-11-09	1994-05-17	Bioject Inc.	Needleless hypodermic injection device
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
US5190521A (en)	1990-08-22	1993-03-02	Tecnol Medical Products, Inc.	Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en)	1990-12-13	1996-06-18	Elan Medical Technologies Limited	Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en)	1991-08-23	1991-10-09	Weston Terence E	Needle-less injector
SE9102652D0 (sv)	1991-09-13	1991-09-13	Kabi Pharmacia Ab	Injection needle arrangement
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5328483A (en)	1992-02-27	1994-07-12	Jacoby Richard M	Intradermal injection device with medication and needle guard
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
US5569189A (en)	1992-09-28	1996-10-29	Equidyne Systems, Inc.	hypodermic jet injector
US5334144A (en)	1992-10-30	1994-08-02	Becton, Dickinson And Company	Single use disposable needleless injector
TW333456B (en)	1992-12-07	1998-06-11	Takeda Pharm Ind Co Ltd	A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
WO1994020505A1 (en) *	1993-03-12	1994-09-15	The Upjohn Company	Crystalline ceftiofur free acid
US6087324A (en)	1993-06-24	2000-07-11	Takeda Chemical Industries, Ltd.	Sustained-release preparation
WO1995024176A1 (en)	1994-03-07	1995-09-14	Bioject, Inc.	Ampule filling device
US5466220A (en)	1994-03-08	1995-11-14	Bioject, Inc.	Drug vial mixing and transfer device
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5599302A (en)	1995-01-09	1997-02-04	Medi-Ject Corporation	Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en)	1995-10-10	1998-03-24	Visionary Medical Products Corporation, Inc.	Gas pressured needle-less injection device and method
WO1997001331A2 (en)	1995-06-27	1997-01-16	Takeda Chemical Industries, Ltd.	Method of producing sustained-release preparation
TW448055B (en)	1995-09-04	2001-08-01	Takeda Chemical Industries Ltd	Method of production of sustained-release preparation
JP2909418B2 (ja)	1995-09-18	1999-06-23	株式会社資生堂	薬物の遅延放出型マイクロスフイア
US5893397A (en)	1996-01-12	1999-04-13	Bioject Inc.	Medication vial/syringe liquid-transfer apparatus
US5980945A (en)	1996-01-16	1999-11-09	Societe De Conseils De Recherches Et D'applications Scientifique S.A.	Sustained release drug formulations
GB9607549D0 (en)	1996-04-11	1996-06-12	Weston Medical Ltd	Spring-powered dispensing device
US6264970B1 (en)	1996-06-26	2001-07-24	Takeda Chemical Industries, Ltd.	Sustained-release preparation
US6419961B1 (en)	1996-08-29	2002-07-16	Takeda Chemical Industries, Ltd.	Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en)	1996-10-09	1998-04-09	Sumitomo Pharmaceuticals Co., Ltd.	Sustained release formulation
ES2221019T3 (es)	1996-10-31	2004-12-16	Takeda Chemical Industries, Ltd.	Preparacion de liberacion mantenida.
ZA9711385B (en)	1996-12-20	1999-06-18	Takeda Chemical Industries Ltd	Method of producing a sustained-release preparation
US5891474A (en)	1997-01-29	1999-04-06	Poli Industria Chimica, S.P.A.	Time-specific controlled release dosage formulations and method of preparing same
US5993412A (en)	1997-05-19	1999-11-30	Bioject, Inc.	Injection apparatus
CO4940418A1 (es)	1997-07-18	2000-07-24	Novartis Ag	Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
JP2001519346A (ja)	1997-10-07	2001-10-23	シェーリングコーポレイション	抗真菌性結晶性多形物
IT1298087B1 (it)	1998-01-08	1999-12-20	Fiderm S R L	Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6613358B2 (en)	1998-03-18	2003-09-02	Theodore W. Randolph	Sustained-release composition including amorphous polymer
KR19990085365A (ko)	1998-05-16	1999-12-06	허영섭	지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en)	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PL208137B1 (pl)	2001-06-22	2011-03-31	Boehringer Ingelheim Pharma	Bezwodny krystaliczny bromek tiotropium, sposób jego wytwarzania i zastosowanie krystalicznego monohydratu bromku tiotropium do wytwarzania krystalicznego bezwodnego bromku tiotropium
USRE40794E1 (en) *	2001-09-26	2009-06-23	Merck & Co., Inc.	Crystalline forms of carbapenem antibiotics and methods of preparation
DE10153737A1 (de)	2001-10-31	2003-05-28	Boehringer Ingelheim Pharma	Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
TWI378923B (en)	2003-08-15	2012-12-11	Novartis Ag	Pyrimidine derivatives
WO2008091532A1 (en) *	2007-01-19	2008-07-31	Panacos Pharmaceuticals, Inc.	Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
EP2300013B2 (en) *	2008-05-21	2024-11-13	Takeda Pharmaceutical Company Limited	Phosphorous derivatives as kinase inhibitors
PH12013501254A1 (en)	2010-12-17	2016-07-29	Novartis Ag	Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine

2015
- 2015-10-21 KR KR1020177012620A patent/KR102331856B1/ko active Active
- 2015-10-21 SG SG11201702980QA patent/SG11201702980QA/en unknown
- 2015-10-21 UA UAA201704816A patent/UA119794C2/uk unknown
- 2015-10-21 CR CR20170146A patent/CR20170146A/es unknown
- 2015-10-21 EP EP15787846.3A patent/EP3209647B1/en active Active
- 2015-10-21 TN TN2017000157A patent/TN2017000157A1/en unknown
- 2015-10-21 KR KR1020217037870A patent/KR20210142781A/ko not_active Ceased
- 2015-10-21 MY MYPI2017701381A patent/MY192216A/en unknown
- 2015-10-21 CN CN202010394526.8A patent/CN111825717A/zh active Pending
- 2015-10-21 DK DK15787846.3T patent/DK3209647T3/da active
- 2015-10-21 PT PT157878463T patent/PT3209647T/pt unknown
- 2015-10-21 LT LTEP15787846.3T patent/LT3209647T/lt unknown
- 2015-10-21 CA CA2965169A patent/CA2965169C/en active Active
- 2015-10-21 EP EP20177579.8A patent/EP3760618A1/en active Pending
- 2015-10-21 PH PH1/2017/500732A patent/PH12017500732B1/en unknown
- 2015-10-21 CN CN201580069762.XA patent/CN107108559B/zh active Active
- 2015-10-21 PE PE2017000740A patent/PE20171344A1/es unknown
- 2015-10-21 ES ES15787846T patent/ES2813726T3/es active Active
- 2015-10-21 CN CN202010394064.XA patent/CN111888368B/zh active Active
- 2015-10-21 US US15/520,694 patent/US10385078B2/en active Active
- 2015-10-21 HU HUE15787846A patent/HUE051693T2/hu unknown
- 2015-10-21 WO PCT/US2015/056701 patent/WO2016065028A1/en not_active Ceased
- 2015-10-21 JP JP2017522531A patent/JP6633072B2/ja active Active
- 2015-10-21 RS RS20201049A patent/RS60737B1/sr unknown
- 2015-10-21 HR HRP20201343TT patent/HRP20201343T1/hr unknown
- 2015-10-21 CN CN202411678661.XA patent/CN119735613A/zh active Pending
- 2015-10-21 MX MX2017005120A patent/MX2017005120A/es active IP Right Grant
- 2015-10-21 EA EA201790892A patent/EA035145B1/ru not_active IP Right Cessation
- 2015-10-21 AU AU2015335950A patent/AU2015335950B2/en active Active
- 2015-10-21 SI SI201531327T patent/SI3209647T1/sl unknown
2017
- 2017-04-18 ZA ZA2017/02737A patent/ZA201702737B/en unknown
- 2017-04-20 IL IL251818A patent/IL251818B/en active IP Right Grant
- 2017-04-20 CL CL2017000979A patent/CL2017000979A1/es unknown
- 2017-04-20 DO DO2017000101A patent/DOP2017000101A/es unknown
- 2017-05-10 CO CONC2017/0004714A patent/CO2017004714A2/es unknown
- 2017-05-18 EC ECIEPI201730878A patent/ECSP17030878A/es unknown
2019
- 2019-06-03 US US16/429,988 patent/US10934317B2/en active Active
- 2019-12-11 JP JP2019223360A patent/JP2020063276A/ja active Pending
2020
- 2020-09-02 CY CY20201100826T patent/CY1123295T1/el unknown
- 2020-12-16 US US17/124,407 patent/US11427605B2/en active Active
- 2020-12-31 IL IL279910A patent/IL279910A/en unknown
2023
- 2023-08-08 US US18/366,976 patent/US20240043457A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP3760618A1 (en)	2021-01-06
ECSP17030878A (es)	2018-01-31
EP3209647A1 (en)	2017-08-30
WO2016065028A8 (en)	2016-06-30
MX2017005120A (es)	2018-02-12
EP3209647B1 (en)	2020-06-03
PH12017500732B1 (en)	2022-06-17
US20180037597A1 (en)	2018-02-08
EA035145B1 (ru)	2020-05-06
US11427605B2 (en)	2022-08-30
RS60737B1 (sr)	2020-09-30
CN111888368B (zh)	2024-02-02
PT3209647T (pt)	2020-09-10
IL251818A0 (en)	2017-06-29
IL279910A (en)	2021-03-01
CA2965169A1 (en)	2016-04-28
SG11201702980QA (en)	2017-05-30
KR20170072905A (ko)	2017-06-27
JP2020063276A (ja)	2020-04-23
NZ730940A (en)	2021-10-29
CL2017000979A1 (es)	2018-01-05
WO2016065028A1 (en)	2016-04-28
ES2813726T3 (es)	2021-03-24
CN111825717A (zh)	2020-10-27
CN119735613A (zh)	2025-04-01
PH12017500732A1 (en)	2017-10-09
US20210355146A1 (en)	2021-11-18
PE20171344A1 (es)	2017-09-13
UA119794C2 (uk)	2019-08-12
US10385078B2 (en)	2019-08-20
KR20210142781A (ko)	2021-11-25
EA201790892A1 (ru)	2018-03-30
US20200010493A1 (en)	2020-01-09
CN107108559B (zh)	2020-06-05
JP2017535538A (ja)	2017-11-30
IL251818B (en)	2021-01-31
JP6633072B2 (ja)	2020-01-22
DK3209647T3 (da)	2020-08-24
CY1123295T1 (el)	2020-11-25
CN107108559A (zh)	2017-08-29
DOP2017000101A (es)	2017-06-30
AU2015335950B2 (en)	2018-01-25
HRP20201343T1 (hr)	2020-11-27
US10934317B2 (en)	2021-03-02
TN2017000157A1 (en)	2018-10-19
SI3209647T1 (sl)	2021-01-29
CN111888368A (zh)	2020-11-06
LT3209647T (lt)	2020-09-25
AU2015335950A1 (en)	2017-05-04
MY192216A (en)	2022-08-09
KR102331856B1 (ko)	2021-11-29
CA2965169C (en)	2021-11-16
ZA201702737B (en)	2018-12-19
HUE051693T2 (hu)	2021-03-29
CR20170146A (es)	2017-08-10
US20240043457A1 (en)	2024-02-08

Publication	Publication Date	Title
CL2017000979A1 (es)	2018-01-05	Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina
CL2017003107A1 (es)	2018-04-02	Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak
MX2021001231A (es)	2021-04-12	Compuestos heterociclicos y sus usos.
ECSP15043696A (es)	2017-07-31	Compuestos de heteroarilo y sus usos
MX2016015565A (es)	2017-07-04	Ciertos inhibidores de la proteina quinasa.
MX2016010213A (es)	2017-04-13	Formulaciones farmaceuticas novedosas.
MX2015011514A (es)	2016-08-11	Compuestos de heteroarilo y sus usos.
CR20150524A (es)	2015-12-01	Compuestos de heteroarilo y sus usos
BR112019001607A2 (pt)	2019-04-30	inibidores macrocíclicos de quinases
ECSP16074478A (es)	2018-07-31	Compuestos novedosos
ECSP16093323A (es)	2017-01-31	N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida
MX2017013875A (es)	2018-06-22	Ciertos inhibidores de la proteína quinasa.
MX374555B (es)	2025-03-04	Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
UY36117A (es)	2016-01-08	Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
UY37551A (es)	2018-07-31	Activador de nrf2
UY35876A (es)	2015-07-31	Derivados de pirazolopirimidin-2-ilo como inhibidores de jak
MX2018005987A (es)	2018-11-29	Compuestos heterociclicos para el tratamiento de enfermedades.
MX2018013573A (es)	2019-08-01	Ciertos inhibidores de la proteína cinasa.
MX381590B (es)	2025-03-12	Una forma cristalina de clorhidrato de éster butílico del ácido 4-((r)-2-{[6-((s)-3-metoxi-pirrolidina-1-il)-2-fenil-pirimidina-4-carbonil]-amino}-3-fosfonopropionil)-piperazin-1-carboxílico.
AR108616A1 (es)	2018-09-12	Formulación combinada de tres compuestos antivirales
UY36958A (es)	2017-05-31	Compuestos para administración intracelular
DOP2016000322A (es)	2016-12-30	N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida